1. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee;Vasey;Clin. Cancer Res.,1999
2. Trends and developments in liposome drug delivery systems;Lian;J. Pharm. Sci.,2001
3. Nanoparticle therapeutics: an emerging treatment modality for cancer;Davis;Nat. Rev. Drug Discov.,2008
4. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review);Orditura;Oncol. Rep.,2004
5. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs;Matsumura;Cancer Res.,1986